InflaRx N.V. (IFRX)

DE — Healthcare Sector
Peers: GBIO  KRON  ERAS  CCCC  EWTX  KZR  FULC  PASG  ABOS  GRTX  INZY  ELDN  ICVX  OCUP  RVPH  PLX  EYPT  SLS  GLUE  DSGN  HOWL  IKNA  STOK 

Automate Your Wheel Strategy on IFRX

With Tiblio's Option Bot, you can configure your own wheel strategy including IFRX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol IFRX
  • Rev/Share 0.002
  • Book/Share 1.113
  • PB 0.6716
  • Debt/Equity 0.01
  • CurrentRatio 5.284
  • ROIC -0.7518

 

  • MktCap 50181666.8274
  • FreeCF/Share -0.7541
  • PFCF -1.051
  • PE -1.0582
  • Debt/Assets 0.0081
  • DivYield 0
  • ROE -0.6403

 

  • Rating B-
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 3
  • P/B Score 4
  • D/E Score 4

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Downgrade IFRX Raymond James Strong Buy Outperform -- $2 May 29, 2025
Initiation IFRX Cantor Fitzgerald -- Overweight -- $10 April 29, 2025

News

InflaRx Ends Lead Asset Development After Failed Study For Rare And Painful Skin Disease
IFRX
Published: May 28, 2025 by: Benzinga
Sentiment: Negative

InflaRx N.V. IFRX on Wednesday announced that the Independent Data Monitoring Committee (IDMC) conducting the unblinded interim analysis for the Phase 3 trial for vilobelimab in pyoderma gangrenosum (PG) recommended that the trial be stopped due to futility.

Read More
image for news InflaRx Ends Lead Asset Development After Failed Study For Rare And Painful Skin Disease
InflaRx to Participate in Upcoming Investor Conferences
IFRX
Published: May 22, 2025 by: GlobeNewsWire
Sentiment: Neutral

JENA, Germany, May 22, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the Company will participate in multiple investor conferences in June and July 2025.

Read More
image for news InflaRx to Participate in Upcoming Investor Conferences
InflaRx Reports First Quarter 2025 Financial Results and Provides Business Update
IFRX
Published: May 07, 2025 by: GlobeNewsWire
Sentiment: Neutral

JENA, Germany, May 07, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced its financial results for the three months ended March 31, 2025, and provided a business update.

Read More
image for news InflaRx Reports First Quarter 2025 Financial Results and Provides Business Update
InflaRx to Report First Quarter 2025 Results on May 7, 2025
IFRX
Published: April 30, 2025 by: GlobeNewsWire
Sentiment: Neutral

JENA, Germany, April 30, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that it will report its first quarter 2025 financial and operating results on May 7, 2025, before the market opens. No conference call is planned.

Read More
image for news InflaRx to Report First Quarter 2025 Results on May 7, 2025
InflaRx (IFRX) Loses -15.29% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
IFRX
Published: March 26, 2025 by: Zacks Investment Research
Sentiment: Negative

InflaRx (IFRX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Read More
image for news InflaRx (IFRX) Loses -15.29% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
InflaRx Reports Full Year 2024 Results and Highlights Key Achievements and Expected Milestones
IFRX
Published: March 20, 2025 by: GlobeNewsWire
Sentiment: Neutral

JENA, Germany, March 20, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced its financial results for the year ended December 31, 2024, highlighting recent operational achievements and expected milestones for 2025.

Read More
image for news InflaRx Reports Full Year 2024 Results and Highlights Key Achievements and Expected Milestones
InflaRx to Showcase Vilobelimab's Role in Immuno-Dermatology at the 2025 AAD Annual Meeting
IFRX
Published: February 28, 2025 by: GlobeNewsWire
Sentiment: Neutral

JENA, Germany, Feb. 28, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced acceptance of all submitted abstracts, featuring the role of vilobelimab in pyoderma gangrenosum (PG) and hidradenitis suppurativa (HS), to be presented during the 2025 American Academy of Dermatology (AAD) Annual Meeting, March 7 - 11, in Orlando, FL.

Read More
image for news InflaRx to Showcase Vilobelimab's Role in Immuno-Dermatology at the 2025 AAD Annual Meeting
InflaRx Announces Closing of $30 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
IFRX
Published: February 18, 2025 by: GlobeNewsWire
Sentiment: Neutral

JENA, Germany, Feb. 18, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX) (the “Company”), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, announced today that it has completed its underwritten public offering of 8,250,000 ordinary shares of the Company at a public offering price of $2.00 per ordinary share and in lieu of ordinary shares to certain investors, pre-funded warrants to purchase up to 6,750,000 of the Company's ordinary shares.

Read More
image for news InflaRx Announces Closing of $30 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
InflaRx Announces Pricing of $30 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
IFRX
Published: February 13, 2025 by: GlobeNewsWire
Sentiment: Neutral

JENA, Germany, Feb. 13, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX) (the “Company”), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, announced today the pricing of its underwritten public offering of 8,250,000 ordinary shares of the Company at an offering price of $2.00 per ordinary share and in lieu of ordinary shares to certain investors, pre-funded warrants to purchase up to 6,750,000 of the Company's ordinary shares. The purchase price of each pre-funded warrant is equal to the price per share at which ordinary shares are being sold to the public in this offering, minus $0.001, which …

Read More
image for news InflaRx Announces Pricing of $30 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
InflaRx Announces Public Offering of Ordinary Shares and Pre-Funded Warrants
IFRX
Published: February 13, 2025 by: GlobeNewsWire
Sentiment: Neutral

JENA, Germany, Feb. 13, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX) (the “Company”), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, announced today that it has commenced an underwritten public offering of ordinary shares of the Company, and in lieu of ordinary shares to certain investors, pre-funded warrants to purchase the Company's ordinary shares. The purchase price of each pre-funded warrant will equal the price per share at which ordinary shares are being sold to the public in this offering, minus $0.001, which will be the exercise price of each pre-funded warrant. All ordinary shares and pre-funded …

Read More
image for news InflaRx Announces Public Offering of Ordinary Shares and Pre-Funded Warrants

About InflaRx N.V. (IFRX)

  • IPO Date 2017-11-07
  • Website https://www.inflarx.de
  • Industry Biotechnology
  • CEO Dr. Niels C. Riedemann M.D., Ph.D.
  • Employees 74

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company also develops INF904, an oral, small molecule drug candidate for the undisclosed chronic inflammatory and autoimmune diseases; and IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.